TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04260451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation
Description: Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation.
Study: NCT06267287

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological examination of the patient's biological material and determination of antibiotic resistance
Description: Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
Study: NCT00893438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitNet treatment
Description: web-based cognitive behavioural treatment for adolescents with CFS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care treatment for adolescents with CFS
Study: NCT00082225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45 antibodies
Description: The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV specific T cells
Description: The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2
Study: NCT03819530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin and Mineral Powder
Description: Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
Study: NCT03992248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Eating for at least 14hrs per day.
Study: NCT00638560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C, Vitamin E
Description: Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant treatment
Description: no treatment
Study: NCT00789867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pGM169/GL67A
Description: Received a nebulized dose via an breath-actuated nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pGM169/GL67A
Description: Received a nebulized dose via an breath-actuated nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pGM169/GL67A
Description: Received a nebulized dose via an breath-actuated nebulizer
Study: NCT04727203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AHAA
Description: Multi-component healthy lifestyle program
Study: NCT04035850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine Tablets
Description: Strength 5-20 mg
Study: NCT00726622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open laparotomy and rectal resection
Description: Patients undergo open laparotomy and rectal resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted rectal resection
Description: Patients undergo laparoscopic-assisted rectal resection.
Study: NCT01782365

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM stimulation
Description: no stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0,75 Hz stimulation
Study: NCT05747508

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INOpulse®
Description: Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long Term Follow Up
Description: Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
Study: NCT03808688

Intervention type: DRUG
Group type: OTHER
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: 1 drop in each eye once daily in the evening
Study: NCT00627029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
Study: NCT04389190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy settings for image acquisition
Description: X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy settings for image acquisition
Description: X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy settings for image acquisition
Description: X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
Study: NCT01909648

Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood withdrawal
Study: NCT04066049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMT en Español
Description: EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser \& Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
Study: NCT01708239

Intervention type: OTHER
Intervention: Left rule, D-dimer measurement and complete ultrasonography in pregnant women.
Description: Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
Study: NCT04767737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topically Administered Lavender Aromatherapy
Description: 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topically Administered Water
Description: 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
Study: NCT02917668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2
Description: Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2
Description: Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Oxygen delivery manually titrated by the nursing staff for a SpO2 target of \> or = 95 %

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Oxygen delivery manually titrated by the nursing staff for a SpO2 target of \> or = 95 %
Study: NCT00376181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Azilsartan
Description: Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Azilsartan
Description: Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
Study: NCT04358510

Intervention type: DEVICE
Intervention: COViage
Description: The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
Study: NCT01516658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel coil
Description: at least one Hydrogel coil have to use for embolization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare platinum coil
Description: only bare platinum coil have to use for embolization
Study: NCT03053258

Intervention type: DEVICE
Intervention: Collection of exhaled breath sample
Description: Collect exhaled breath sample from patients with suspected VAP
Study: NCT04328779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The multi-task overground walking training
Description: The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The multi-task treadmill walking training
Description: The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
Study: NCT02500667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg QD
Study: NCT00860951

Intervention type: DEVICE
Group type: OTHER
Intervention: Brain Computer Interface Keyboard
Description: Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
Study: NCT03599557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV communication intervention
Description: This intervention will be communication skills training.
Study: NCT01873716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
Study: NCT04415658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
Study: NCT01650285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2
Study: NCT02114775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: 0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
Study: NCT01726452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin / Oxaliplatin
Description: Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Flourouracil/ Capecitabine
Description: 5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (41.4 Gy/23 fractions)
Description: Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², day 1 of each cycle (i.e. every 14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², day 1 of each cycle (i.e. every 14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
Study: NCT04295447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: 1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: 1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 60Mg Tab
Description: (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
Study: NCT04254380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Lispro Injection
Description: Route of administration: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Route of administration: subcutaneous injection
Study: NCT00460083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel(R) (pimecrolimus 1%)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiCeram(R) -ceramide based barrier repair cream
Study: NCT01794533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with Epinephrine+ Normal saline
Description: local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine with Epinephrine+ Normal saline
Description: local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with Epinephrine + fentanyl
Description: local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine with Epinephrine + fentanyl
Description: local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
Study: NCT04634981

Intervention type: PROCEDURE
Intervention: anesthesia of emergency cesarean section
Description: compare General versus spinal anesthesia

Intervention type: PROCEDURE
Intervention: anesthesia of emergency cesarean section
Description: compare General versus spinal anesthesia
Study: NCT00907257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl peroxide wash
Description: 5% benzoyl peroxide wash

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzoyl peroxide wash
Description: 5% benzoyl peroxide wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin gel
Description: 0.04% tretinoin gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin gel
Description: 0.04% tretinoin gel
Study: NCT02618005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Description: Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
Study: NCT02228187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface
Description: Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
Study: NCT00960908

Intervention type: DEVICE
Intervention: Endeavor Resolute stents
Description: 2nd generation ZES

Intervention type: DEVICE
Intervention: Endeavor Sprint stent
Description: 1st generation ZES
Study: NCT00962156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch 130/0.4
Description: Infusion for volume expansion in the ICU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers acetate
Description: Infusion for volume expansion in the ICU
Study: NCT01145014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 2 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 10 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 20 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 50 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 100 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 150 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 200 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 400 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 600 mg oral drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 10,0 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 50,0 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo (oral drinking solution and IR tablets)
Study: NCT03459599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic antibiotics
Description: Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No prophylaxis (Amox-clav withheld)
Description: Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients